TWI907332B - 使用嘧啶二酮化合物治療肥厚性心肌症 - Google Patents

使用嘧啶二酮化合物治療肥厚性心肌症

Info

Publication number
TWI907332B
TWI907332B TW107127110A TW107127110A TWI907332B TW I907332 B TWI907332 B TW I907332B TW 107127110 A TW107127110 A TW 107127110A TW 107127110 A TW107127110 A TW 107127110A TW I907332 B TWI907332 B TW I907332B
Authority
TW
Taiwan
Prior art keywords
compound
individual
dose
daily dose
treatment
Prior art date
Application number
TW107127110A
Other languages
English (en)
Chinese (zh)
Other versions
TW201916882A (zh
Inventor
馬可 Ｊ 賽米葛恩
朱恩 Ｈ 李
喬瑟夫 藍賓
艾瑞克 葛林
馬可 艾文奇克
湯姆士 卡爾森
中偉 張
Original Assignee
美商邁奧卡迪亞公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商邁奧卡迪亞公司 filed Critical 美商邁奧卡迪亞公司
Publication of TW201916882A publication Critical patent/TW201916882A/zh
Application granted granted Critical
Publication of TWI907332B publication Critical patent/TWI907332B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
TW107127110A 2017-08-04 2018-08-03 使用嘧啶二酮化合物治療肥厚性心肌症 TWI907332B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15

Publications (2)

Publication Number Publication Date
TW201916882A TW201916882A (zh) 2019-05-01
TWI907332B true TWI907332B (zh) 2025-12-11

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107127110A TWI907332B (zh) 2017-08-04 2018-08-03 使用嘧啶二酮化合物治療肥厚性心肌症

Country Status (28)

Country Link
US (6) US20200054636A1 (https=)
EP (2) EP3661514B1 (https=)
JP (3) JP2020529996A (https=)
KR (2) KR20200035973A (https=)
CN (2) CN111182901A (https=)
AU (2) AU2018311974B2 (https=)
CA (1) CA3071948A1 (https=)
DK (1) DK3661514T3 (https=)
ES (1) ES3055679T3 (https=)
FI (1) FI3661514T3 (https=)
HR (1) HRP20251598T1 (https=)
HU (1) HUE073047T2 (https=)
IL (2) IL322175A (https=)
LT (1) LT3661514T (https=)
MA (1) MA49760B1 (https=)
MX (3) MX2020001406A (https=)
MY (1) MY208231A (https=)
PL (1) PL3661514T3 (https=)
PT (1) PT3661514T (https=)
RS (1) RS67534B1 (https=)
RU (1) RU2020109345A (https=)
SG (2) SG10202112960QA (https=)
SI (1) SI3661514T1 (https=)
SM (1) SMT202500413T1 (https=)
TW (1) TWI907332B (https=)
UA (1) UA130213C2 (https=)
UY (1) UY37834A (https=)
WO (1) WO2019028360A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
EP4054588A4 (en) * 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
HUE069154T2 (hu) * 2020-01-28 2025-02-28 Assia Chem Ind Ltd A mavakamten szilárd állapotú formái és eljárás elõállításukra
MX2023002024A (es) * 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
PT4370116T (pt) * 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
US20240389972A1 (en) * 2021-09-24 2024-11-28 Koninklijke Philips N.V. METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473576A (zh) * 2013-06-21 2016-04-06 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473576A (zh) * 2013-06-21 2016-04-06 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物

Also Published As

Publication number Publication date
IL272300B1 (en) 2025-08-01
EP4659806A2 (en) 2025-12-10
MX2024000348A (es) 2024-01-26
CN118593507A (zh) 2024-09-06
LT3661514T (lt) 2025-11-10
US20260007671A1 (en) 2026-01-08
MA49760B1 (fr) 2025-11-28
PL3661514T3 (pl) 2026-02-23
AU2024203872A1 (en) 2024-06-27
US20200054636A1 (en) 2020-02-20
IL272300A (en) 2020-03-31
CA3071948A1 (en) 2019-02-07
RS67534B1 (sr) 2026-01-30
MY208231A (en) 2025-04-25
EP3661514A1 (en) 2020-06-10
DK3661514T3 (da) 2025-12-15
HRP20251598T1 (hr) 2026-01-30
SI3661514T1 (sl) 2026-01-30
JP2025020292A (ja) 2025-02-12
SG11202000549TA (en) 2020-02-27
MA49760A (fr) 2020-06-10
US20240423981A1 (en) 2024-12-26
AU2018311974A1 (en) 2020-02-06
SMT202500413T1 (it) 2025-11-10
CN111182901A (zh) 2020-05-19
EP4659806A3 (en) 2026-02-18
FI3661514T3 (fi) 2025-12-12
IL272300B2 (en) 2025-12-01
JP2023065372A (ja) 2023-05-12
KR20250116181A (ko) 2025-07-31
RU2020109345A (ru) 2021-09-06
PT3661514T (pt) 2025-12-10
JP2020529996A (ja) 2020-10-15
US20220226324A1 (en) 2022-07-21
KR20200035973A (ko) 2020-04-06
WO2019028360A1 (en) 2019-02-07
MX2020001406A (es) 2020-03-09
AU2018311974B2 (en) 2024-03-07
SG10202112960QA (en) 2021-12-30
HUE073047T2 (hu) 2025-12-28
MX2024008096A (es) 2024-07-15
EP3661514B1 (en) 2025-09-17
TW201916882A (zh) 2019-05-01
UA130213C2 (uk) 2025-12-24
IL322175A (en) 2025-09-01
US20220313695A1 (en) 2022-10-06
US20250213565A1 (en) 2025-07-03
ES3055679T3 (en) 2026-02-13
UY37834A (es) 2019-02-28

Similar Documents

Publication Publication Date Title
TWI907332B (zh) 使用嘧啶二酮化合物治療肥厚性心肌症
AU2009252897B2 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
TW201002676A (en) Use of dronedarone for the preparation of a medicament for use in the prevention of permanent atrial fibrillation
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
CN102065856A (zh) 决奈达隆与至少一种利尿药的组合及其治疗用途
HK40026724A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
HK40026724B (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
HK40028703A (zh) 用於在肥厚型心肌病的治疗中使用的玛伐凯泰
TW202539641A (zh) 用於治療心臟病之方法
HK1156502A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2017153850A1 (en) Perhexiline dosing regimens for use in the treatment of hypertrophic cardiomyopathy